Faculty Presenters. Leonard M. Fromer, MD Executive Medical Director Group Practice Forum Los Angeles, California
|
|
- Nathaniel Armstrong
- 6 years ago
- Views:
Transcription
1
2 Faculty Presenters Leonard M. Fromer, MD Executive Medical Director Group Practice Forum Los Angeles, California Frank C. Sciurba, MD Associate Professor of Medicine Medical Director, Pulmonary Physiology Laboratory, Division of Pulmonary, Allergy and Critical Care Medicine University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania
3 Disclosures Leonard M. Fromer, MD Consultant Mylan Speakers Bureau Boehringer Ingelheim Frank C. Sciurba, MD Research Support AstraZeneca, Boehringer Ingelheim, Commonwealth of Pennsylvania, COPD Foundation, GlaxoSmithKline, National Institutes of Health (NIH), PneumRx, Pulmonx, Respironics Scientific Advisory Board GlaxoSmithKline, Boehringer Ingelheim
4 Learning Objectives Recognize risk factors and early symptoms of COPD Summarize the current clinical guidelines for the optimal management of COPD Devise a treatment plan for COPD patients that includes the appropriate use of bronchodilators Evaluate inhaler use among COPD patients
5 Definition and Early Symptoms of COPD Common, preventable, treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities caused by significant exposure to noxious particles or gases 1 Umbrella term for progressive lung diseases, including 2 Emphysema Chronic bronchitis Refractory (nonreversible) asthma/asthma COPD overlap syndrome Some forms of bronchiectasis Most common early symptoms 3 Dyspnea on exertion Chronic cough Abnormal sputum production 1 Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/ 2 COPD Foundation. is COPD/Understanding COPD/What is COPD.aspx 3 Fromer L. Intern J Gen Med. 2011;4:
6 Epidemiology of COPD United States 1,2 Third leading cause of death Number affected: 13.7 million Age adjusted prevalence among individuals 25 y: 6.5% Now affects more women than men Incidence is increasing among younger individuals (ages 45 64) Worldwide 3,4 Fourth leading cause of death Number affected: 384 million Prevalence among individuals 30 y: 11.4% Prevalence is expected to increase with increasing prevalence of smoking in developing countries and increasing age of populations in high income countries 1 Ford ES et al. CHEST. 2013:144: Kochanek D, et al. Natl Vital Stat Rep. 2016;65 (4). 3 Adeloye D, et al. J Global Health : World Health Organization.
7 COPD Deaths by Gender, CDC. NVSR, Modified from the American Lung Association Disparities in Lung Health. Taking Her Breath Away initiatives/research/lung health disparities/the rise of copd in women.html?referrer=
8 Etiology and Pathophysiology of COPD ETIOLOGY/RISK FACTORS Environmental factors Smoking Pollutants/particle exposure Host factors Genetics Age Gender Lung growth and development Socioeconomic status Asthma/airway hyperreactivity Chronic bronchitis Infections PATHOGENESIS Oxidative stress Protease/antiprotea se imbalance Amplified inflammation Inflammatory mediators Inflammatory cells Fibrosis Peribronchiolar Interstitial PATHOPHYSIOLOGY Airflow limitation Gas trapping Gas exchange abnormalities Mucus hypersecretion Exacerbations Deconditioning Pulmonary hypertension (late stage) Comorbidities
9 The Inactivity Dyspnea Spiral Respiratory impairment Further abstention Dyspnea during mild exertion Further deconditioning Homebound, depression, O 2 therapy, etc Dyspnea during ADL Dyspnea during moderate exertion Abstinence from exercise ADL, activities of daily living. Physical deconditioning Adapted from Denis O Donnell, MD.
10 Comorbidities are Common in COPD Sleep Apnea Lung Cancer Emphysema Anxiety, Depression Pulmonary Hypertension Anemia Cardiovascular Disease Peripheral Muscle Wasting & Dysfunction Osteoporosis Diabetes Metabolic Syndrome Peptic Ulcers GI complications Cachexia Adapted from Kao C et al. Atlas of COPD Barnes PJ et al. Eur Respir J. 2009;33: Fishman A et al. N Engl J Med. 2003;348:
11 COPD and Cardiac Disease: A Common Combination PHC4 provided hospital discharges between Oct. 1, 2007 and Sept. 30, 2008 (n=408,924) 1 COPD: N=57,289 CHF: N=61,475 COPD only N=28,916 COPD + CHF N=8,868 COPD, CHF, CAD N=7,749 CHF only N=23,621 CAD: N=94,699 COPD + CAD N=11,756 CHF, congestive heart failure; CAD, coronary artery disease. CAD only N=53,957 CHF + CAD N=21, % of COPD discharges have comorbid CHF and/or CAD 1 COPD is an independent risk factor for cardiovascular disease mortality 2 1 Pittsburgh Regional Health Initiative Courtesy of Brian W. Carlin, MD. 2 Finkelstein J, et al. J COPD. 2009;4:
12 Case 1: Burt J. Burt is a 42 y o IT specialist who recently quit smoking (2 pk/d habit from age y). He is in the office for a routine checkup. All vitals are normal except for slightly elevated blood pressure. He is 6 tall and weighs 205 lbs. He reports ongoing fatigue that he attributes to recovering from a chest cold. Recent medical history is significant for 2 episodes of acute bronchitis, 1 and 2 years previous.
13 Case 1: Question Should Burt be screened for COPD? 1. Only if he reports dyspnea 2. No, because there is no evidence of cough 3. Yes, because he is a former smoker 4. No, because he is too young to have COPD
14 The Argument for Selective Screening: The COPD Population Screener 1. During the past 4 weeks, how much of the time did you feel short of breath? None of the time A little of the time Some of the time Most of the time Do you ever cough up any stuff, such as mucus or phlegm? No, never Only with Yes, a few days a Yes, most days of occasional colds or month the week chest infections Please select the answer that best describes you in the past 12 months. I do less than I used to because of my breathing problems. Strongly disagree Disagree Unsure Agree Have you smoked at least 100 cigarettes in your ENTIRE LIFE? No Yes How old are you? Age years 0 Age years 1 Age years 2 All of the time 2 Yes, every day 2 Strongly Agree Don t know 0 2 Age 70+ years 2 COPD Foundation. Martinez FJ, et al. COPD. 2008;5:85 95.
15 Indicators for Pursuing a Diagnosis of COPD Dyspnea that is persistent, progressive over time, worse with exercise Patients may avoid exertion, so ask how are you doing? AND what are you doing? Chronic cough Intermittent Recurrent wheezing/chest tightness Productive or unproductive Chronic sputum production Recurrent lower respiratory tract infections History of risk factors such as smoking, indoor air pollution, occupational particle exposure Family history of COPD and/or childhood factors, eg, low birth weight, childhood respiratory infections Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
16 High Index of Suspicion for COPD Screening and Diagnosis Consider COPD in patients with any symptoms and history of exposure to risk factors SYMPTOMS Shortness of breath Chronic cough Sputum RISK FACTORS Host factors Tobacco smoke Occupation Indoor/outdoor air pollution Spirometry is required to make diagnosis Post bronchodilator FEV 1 /FVC <0.70 confirms presence of persistent airflow limitation * *Post bronchodilator FEV 1 /FVC measured min after 2 4 puffs of a short acting bronchodilator. FEV 1, forced expired volume in 1 second; FVC, forced vital capacity. Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
17 Diagnosis: Medical History Smoking Past medical history, e.g., asthma, allergy, respiratory infections in childhood, chronic respiratory/nonrespiratory illnesses Family history of COPD or other chronic respiratory illnesses Patterns of symptom development History of exacerbations or hospitalizations for respiratory illnesses Presence of comorbidities, eg, heart disease, osteoporosis, other conditions that may restrict activity Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
18 Misdiagnoses and Missed Diagnoses 50% of patients with COPD may be misdiagnosed or undiagnosed 1 Contributing factors 2 Lack of awareness of early symptoms Acceptance of symptoms as a consequence of smoking or aging among the general population Symptomatic similarities to asthma Failure of health care providers to use spirometry for diagnosis Potential impact 2 No treatment, inadequate treatment, or inappropriate treatment Unchecked disease progression and rate of decline, with increased frequency/severity of exacerbations and increased hospitalizations Loss of lung function Reduced quality of life Younger age at death 1 Wise RA, et al. Am J Med. 2007;120(8 Suppl 1):S14 S22. 2 Fromer L. Int J Gen Med. 2011;4:
19 Gender Bias: COPD is Less Likely to be Diagnosed in Women Hypothetical Male Patient With COPD Symptoms: Diagnosed as COPD by 65% of physicians Hypothetical Female Patient With Identical COPD Symptoms: Diagnosed as COPD by 49% of physicians COPD symptoms in women are most commonly misdiagnosed as asthma Chapman KR, et al. Chest. 2001;119:
20 Spirometry Incorporate procedure into clinic workflow for appropriate patients Most reproducible/objective measurement of airflow limitation Critical for Confirming diagnosis Assessing prognosis Monitoring response to treatment and treatment adjustments Identifying rapid decline Accuracy depends on appropriate preparation, bronchodilation, technician coaching/patient effort Consider other diagnoses when symptoms are disproportionate to degree of airflow obstruction Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
21 Spirometry: Range of Severity Volume (L) FEV 1 FVC Normal Mild Obstructive Disease Severe Obstructive Disease Time (Seconds)
22 GOLD Refined Combined COPD Assessment Diagnosis Confirmed by Spirometry Postbronchodilator FEV 1 /FVC < 0.7 Assessment of Airflow Limitation GOLD Level FEV 1 (% Predicted) 1 Mild 80 2 Moderate Severe Very Severe < 30 Exacerbation History 2 or 1 leading to hospitalization 0 or 1 not leading to hospitalization Assessment of Symptoms and Risk of Exacerbations C A mmrc 0 1 CAT < 10 D B mmrc 2 CAT 2 Symptoms FEV 1, Forced expiratory volume in 1 second; FVC, forced vital capacity; mmrc, Modified British Research Council Questionnaire; CAT, COPD Assessment Test. Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
23 Asthma COPD Overlap Syndrome Proposed Diagnostic Criteria Major Criteria Marked reversibility with bronchodilators (>15% and >400 ml in FEV 1 ) History of asthma (<40 years of age) Sputum/blood eosinophilia Minor Criteria Reversibility on 2 separate occasions (>12% and >200 ml in FEV 1 ) History of atopy Increased total serum IgE FEV 1, Forced expiratory volume in 1 second. Overlap syndrome: 2 major criteria OR 1 major + 2 minor criteria Soler Cataluña JJ et al. Arch Bronconeumol. 2012;48: Miravitlles M, et al. Arch Bronconeumol. 2014;50:1 16.
24 Does Early Diagnosis Improve Outcomes? FEV 1 (L) Smoking Cessation Slows Lung Function Decline in Mild COPD: Lung Health Study at 11 Years Sustained Quitters Intermittent Quitters Continuous Smokers Year Smoking cessation even at early stages of disease slows the decline of lung function. Does early detection of COPD with spirometry increase likelihood of smoking cessation? Figure adapted from Anthonisen NR, et al. Am J Respir Crit Care Med. 2002;166: Calverley et al. Lancet. 2003;362: BMJ Publishing Group.
25 Guidelines for Intervention and Treatment Multiple guidelines available worldwide Global Strategy for Diagnosis, Management, and Prevention of COPD (GOLD Report 2017) 1 ACP/CHEST/ATS/ERS Clinical Practice Guideline: Diagnosis and Management of Stable COPD, Therapeutic recommendations vary; insufficient guidance on use of newer combination therapies 3 ACP, American College of Physicians; CHEST, American College of Chest Physicians; ATS, American Thoracic Society; ERS, European Respiratory Society. 1 Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/ 2 Qaseem A, et al. Ann Intern Med. 2011;155: Han MK, et al. Lancet Respir Med. 2016; 4:
26 Management of COPD: Focus on Prevention and Maintenance Nonpharmacologic interventions Smoking cessation Vaccination (flu and pneumococcal vaccines) Avoidance of indoor/outdoor air pollution Reduce occupational exposure to irritants Physical activity/exercise training Pulmonary rehabilitation Pharmacologic therapy Bronchodilators Antimuscarinic agents Methylxanthines* Corticosteroids Phosphodiesterase 4 inhibitors *Use in COPD is controversial. Goals of therapy Reduce/relieve symptoms Reduce impairment Reduce risk of exacerbations Reduce frequency/severity of exacerbations Decrease long term lung function decline Increase exercise tolerance Reduce hospitalizations and mortality Improve health status and health related quality of life Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/. Qaseem A, et al. Ann Int Med. 2011;155:
27 Nonpharmacologic Interventions GOLD Patient Group A B, C, D Essential Smoking cessation Smoking cessation Pulmonary rehabilitation Recommended Physical activity Physical activity Depends on local guidelines Influenza vaccine Influenza vaccine Pneumococcal vaccine Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
28 Pulmonary Rehabilitation Efficacious, cost effective intervention for improving functional performance, quality of life and decreasing health care utilization in patients with COPD Components Exercise/physical activity training Education/psychosocial support Programs are underused < 2% of patients with COPD have participated in pulmonary rehabilitation Many factors contribute to underuse, eg, health system, physician, and patientrelated factors Coultas D, et al. Clin Pulm Med. 2009;16(4):
29 Pharmacologic Interventions: GOLD Grades A and B Group A Continue, stop, or try alternate class of bronchodilator Group B LAMA + LABA Evaluate Effect Persistent Symptoms * Bronchodilator *Preferred treatment. LAMA, long acting antimuscarinic agent; LABA, long acting 2 adrenergic agent. Long Acting Bronchodilator Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
30 Pharmacologic Interventions: GOLD Grades C and D LAMA + LABA Group C LABA + ICS Consider roflumilast if FEV 1 <50% predicted + chronic bronchitis Group D Consider macrolide in former smokers Further exacerbation(s) * LAMA Further exacerbation(s) LAMA Further exacerbation(s) LAMA +LABA +ICS * LAMA + LABA *Preferred treatment. LAMA, long acting antimuscarinic agent; LABA, long acting 2 adrenergic agent; ICS, inhaled corticosteroid. Persistent symptoms or further exacerbation(s) LABA + ICS Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
31 Pharmacologic Options in COPD Bronchodilators Anti Inflammatory Short Acting Anticholinergic (SAMA): Ipratropium agonists (SABA): Albuterol Levalbuterol Metaproterenol SAMA + SABA: Ipratropium + albuterol Long Acting Anticholinergic (LAMA): Tiotropium Aclidinium (BID) Umeclidinium agonists (LABA) Salmeterol (BID) Formoterol (BID, nebulized) Arformoterol (BID, nebulized) Indacaterol (QD) Olodaterol (QD) LAMA + LABA Umeclidinium + vilanterol Tiotropium + olodaterol Indacaterol + glycopyrrolate (BID) Theophylline (pill) ICS + LABA Fluticasone + salmeterol (bid) Budesonide + formoterol (bid) Fluticasone + vilanterol (qd) PDE 4 inhibitors Roflumilast (pill) Oral steroids Prednisone* Methylprednisolone* *Not FDA approved for use in COPD specifically. SAMA, short acting antimuscarinic agent; SABA, short acting 2 adrenergic agent; LAMA, long acting antimuscarinic agent; LABA, long acting 2 adrenergic agent; ICS, inhaled corticosteroid; PDE 4, phosphodiesterase 4.
32 LABA/ICS vs. LAMA/LABA: FLAME Trial SGRQ C, St. George's Respiratory Questionnaire. Trough FEV 1 and SGRQ C symptom scale were significantly greater in the LABA/LAMA vs the LABA/ICS group From N Engl J Med., Wedzicha, Banerji, Chapman, et al, Indacaterol Glycopyrronium versus Salmeterol Fluticasone for COPD, 374: Copyright 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
33 Wisdom Trial: Withdrawal of ICS in Patients * on LAMA/LABA Long acting Bronchodilators *Pa ents with severe COPD; Tiotropium + salmeterol. From N Engl J Med., Magnussen, Disse, Rodriguez Roisin, et al, Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD, 371: Copyright 2014 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
34 Types of Inhalers Used in COPD Inhaler Type Metered dose Inhalers Pressurized (pmdis) Breath actuated (BA MDIs) Dry Powder Inhalers (DPIs) Soft Mist Inhalers (SMIs) Nebulizers Key Characteristics Short and long acting bronchodilators and combinations Require use of breath actuation technique Can be used with a spacer or holding chamber Suitable for most COPD patients capable of needed breathing control May not be suitable for elderly, confused, or those with hand conditions (e.g., arthritis) Long acting bronchodilators and combinations Breath actuated delivery Require adequate peak respiratory flow Tiotropium; ipratropium albuterol combination Useful for patients with low dexterity Generate a soft, slower moving aerosol plume Require use of breath actuation technique (less so than MDI) Short and long acting bronchodilators Optimal for patients with cognitive or physical barriers to inhaler use May be appropriate for treatment of exacerbations Garvey C, et al. Advance Healthcare Network for NPs and PAs. Posted at practitioners and physicianassistants.advanceweb.com/archives/article Archives/Toward Better COPD Management.aspx on August 8, 2011.
35 Monitoring Treatment Lung function assessments FEV 1 assessed by spirometry Functional capacity assessed by timed walking test Oxygenation at rest using an arterial blood gas sample Symptoms Cough Sputum production/color Dyspnea Change in lung function Fatigue Activity limitation Sleep disturbance Weight loss Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
36 Monitoring Treatment (Cont.) Inquire about Exacerbations: frequency, severity, likely causes Urgent care visits and hospitalizations (including duration of stay and need for mechanical ventilation Smoking status/exposure to smoking Pharmacotherapy Doses of current medications Adherence to treatment regimen Effectiveness of treatment regimen Inhaler technique: CHECK and REVIEW AT EVERY FOLLOW UP APPOINTMENT Side effects of treatment Request imaging Worsening symptoms Exacerbations with purulent sputum Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
37 Case 2: Sandy L. Sandy is a 58 y o former smoker with moderate COPD. She was doing well until recently on combination LAMA + LABA treatment, but she now reports that her symptoms have been increasing, and last month she experienced an exacerbation that sent her to the ED. She was not hospitalized, but she worries that she will be.
38 Case 2: Question Which of the following would be the next step in bringing Sandy s COPD back under control? 1. Revisit her inhaler technique 2. Restage her COPD 3. Switch to a different LABA + LAMA combination 4. Switch to triple therapy with LABA + LAMA + ICS
39 Adherence to Inhaler Therapy in COPD Nonadherence to COPD medications is high 49% do not use inhaled medications as prescribed 31% use ineffective inhaler dosing techniques 50% overuse medications during periods of respiratory distress Factors predicting nonadherence Intentional nonadherence: deliberate discontinuation during periods of symptom remission Unintentional nonadherence: nonadherence to treatment advice due to factors beyond their control Cognitive impairment Physical disability Vision impairment Complex regimens/confusion about regimens Poor understanding of COPD Bryant J, et al. Resp Res. 2013;14:109.
40 Identify and Address Poor Adherence Barriers to Adherence Inadequate education about COPD and therapy 1 Perceived burden of medication regimen 1,2 Device is difficult to use 3 Depressed mood 3 Medication related cost 3 Adverse effects 3 Red Flags for Nonadherence Failure to refill prescriptions Excessive use of rescue medication Frequent exacerbations Rapid decline in FEV 1 1 LaForest L et al. Prim Care Resp J. 2010;19: George J et al. Chest. 2005;128: Restrepo RD et al. Int J COPD. 2008;3:
41 Common Errors in Inhaler Technique, by Inhaler Type Error DPI pmdi BA pmdi pmdi + Spacer Soft Mist Inhaler Failure to remove the mouthpiece cap or device cover X X X X X Incorrect preparation/priming or loading of dose X X X Failure to pierce capsule X Inhaler upside down X X X Breathing out into the device X Firing the device at/after end of inhalation X X Weak or very slow inhalation X X X Open mouth inhalation technique X X Inhaling through the nose X X X X X Stopping inhalation as device is fired X X X X DPI, dry powder inhaler; pmdi, pressurized metered dose inhaler; BA, breath actuated. Newman SP. Eur Respir Rev. 2005;14:
42 Strategies for Improving Adherence to Inhaler Use Delegate education to appropriate staff (eg, PA, NP, or local pharmacist) Match the right device to the patient s unique needs Provide hands on verbal instructions and supplement with written instructions Make sure patient can demonstrate proper technique for each device prescribed before leaving the appointment RE ASSESS THE PATIENT S ABILITY TO USE INHALER(S) AT EVERY FOLLOW UP APPOINTMENT Cate VS. Advance Healthcare Network for NPs and PAs practitioners and physicianassistants.advanceweb.com/features/articles/managing COPD with Inhaler Devices.aspx
43 Exacerbations Acute events characterized by worsening respiratory symptoms that results in a change in therapy 1 Classification 1 Mild: treated with SABDs Moderate: treated with SABDs + antibiotics and/or oral corticosteroids Severe: requires treatment in the emergency room or hospitalization; may be associated with acute respiratory failure Common precipitants 1,2 Respiratory tract infections (viral or bacterial) Pollution Seasonal temperature variations (very cold or very hot, humid temperatures) Risk factors for exacerbations 3 History of prior exacerbations History of wheezing or asthma SABD, short acting bronchodilator. 1 Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/. 2 Hansel NN, et al. COPD. 2016; 13: Hurst JR, et al. N Engl J Med. 2010; 363:
44 Impact of Exacerbations in COPD Patients with Frequent Exacerbations Faster Decline in Lung Function Greater Airway Inflammation Poorer Quality of Life Higher Mortality Adapted from Wedzicha JA, Seemungal TA. Lancet. 2007;370:
45 When Do Exacerbations Require Hospitalization? Severe symptoms, such as sudden worsening of resting dyspnea, high respiratory rate, decreased Sp0 2, change in mental status Acute respiratory failure Onset of new physical findings (e.g., cyanosis, peripheral edema) Failure of response to initial medical management Presence of serious comorbidities (e.g., newly occurring arrhythmia, heart failure) Insufficient support at home Global Initiative for Chronic Obstructive Lung Disease Report. Available at global strategy diagnosis management prevention copd/.
46 Readmission Reduction: Addressing TRANSITIONS OF CARE
47 Conclusions Early, accurate diagnosis of COPD is essential to effective intervention Guidelines are available to inform diagnosis, treatment selection, and monitoring. Bronchodilators, administered using inhalers, are the cornerstone of COPD management Patients require frequent follow up to assess worsening symptoms or decline, adjust treatment as needed, review inhaler practices, and reinforce adherence.
48
Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationWINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT
WINDY CITY WHEEZE: A PREVENTATIVE APPROACH TO COPD MANAGEMENT Thursday, October 25, 2018 Sarah Sungurlu DO Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures I have no actual
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationCOPD Treatable. Preventable.
My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My
More informationPatient Care Transitions in COPD: Improving Collaboration Between Inpatient and Outpatient Providers to Reduce Readmissions
Patient Care Transitions in COPD: Improving Collaboration Between Inpatient and Outpatient Providers to Reduce Readmissions Held in conjunction with Hospital Medicine 2017, SHM s Annual Meeting. Provided
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationCOPD: Applying New Guidelines to Optimizing Evaluation and Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationAt-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)
At-A-Glance Outpatient Management Reference f Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationFact. Objectives 1/6/2016. Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD)
Reducing Hospital Readmissions for Chronic Obstructive Pulmonary Disease (COPD) Jin S. Oh, PharmD Larkin Community Hospital January 10, 2016 Fact COPD is the third leading cause of death in the United
More informationA patient educational resource provided by Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. has no ownership interest in any other organization that advertises or markets its disease management products and services. A patient educational resource provided
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationAnyone who smokes and/or has shortness of breath and sputum production could have COPD
COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationUNDERSTANDING & MANAGING
UNDERSTANDING & MANAGING YOUR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)* *Includes chronic bronchitis, emphysema, or both Boehringer Ingelheim Pharmaceuticals, Inc. has no ownership interest in any
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationConfronting the Challenges of COPD. What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes
Confronting the Challenges of COPD What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes COPD Definition GOLD: Global Initiative for Chronic Obstructive Lung Disease Common, preventable,
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationSupplementary materials
Supplementary materials Table S1 Patient comorbidities by diagnosis Total Asthma n (%) 5348 (148.4) COPD n (%) 4563 (143.4) ACOS n (%) 469 (197.9) No other comorbidities 95 (26.4) 614 (19.3) 27 (11.4)
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationCHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA
CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA GOLD GINA Chronic Obstructive Pulmonary Disease (COPD) COPD is currently the fourth leading cause of death in the world.1 COPD is projected to
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease By: Dr. Fatima Makee AL-Hakak () University of kerbala College of nursing Out lines What is the? Overview Causes of Symptoms of What's the difference between and asthma?
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More information#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA
Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker
More informationAsthma ASTHMA. Current Strategies for Asthma and COPD
Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,
More information